论文部分内容阅读
目的:观察依达拉奉联合纤溶治疗脑梗死的疗效及对高敏C反应蛋白(CRP)的影响。方法:132例脑梗死患者随机分成2组,对照组65例采用纤溶酶治疗,前3d200U/d,静脉滴注,后7d100U/d,疗程10d;观察组67例采用纤溶酶治疗同时予以依达拉奉治疗,30mg静脉滴注2次/d,疗程14d,14d后评定疗效。采用速率散射比浊法测定血CRP含量。结果:观察组和对照组的有效率分别是88.06%和72.31%,差异有统计学意义(P<0.05)。2组治疗后CSS评分及CRP水平均下降,观察组更明显。结论:依达拉奉联合纤溶酶治疗脑梗死安全有效,可能与降低CRP有关。
Objective: To observe the curative effect of edaravone combined with fibrinolytic therapy on cerebral infarction and its effect on high sensitive C-reactive protein (CRP). Methods: 132 patients with cerebral infarction were randomly divided into two groups, the control group of 65 patients treated with plasmin, the first 3d200U / d, intravenous drip, after 7d100U / d, treatment 10d; the observation group of 67 patients treated with plasmin simultaneously Edaravone treatment, 30mg intravenous infusion 2 / d, treatment 14d, 14d after the assessment of efficacy. The blood concentration of CRP was measured by rate nephelometry. Results: The effective rates of the observation group and the control group were 88.06% and 72.31% respectively, the difference was statistically significant (P <0.05). CSS scores and CRP levels decreased in both groups after treatment, and the observation group was more obvious. Conclusion: Edaravone and plasmin are safe and effective in treating cerebral infarction, which may be related to the reduction of CRP.